No. 22-37

Teva Pharmaceuticals USA, Inc. v. GlaxoSmithKline LLC, et al.

from the United States Court of Appeals for the Federal Circuit

See other cases from the Federal Circuit.

Docket Entries

The Solicitor General is invited to file a brief in this case expressing the views of the United States.

Reply of petitioner Teva Pharmaceuticals USA, Inc. filed. (Distributed)

DISTRIBUTED for Conference of 9/28/2022.

Brief of respondents GlaxoSmithKline LLC, et al. in opposition filed.

Brief amicus curiae of Association for Accessible Medicines filed.

Brief amicus curiae of Mylan Pharmaceuticals Inc. filed.

Brief amicus curiae of Alvotech filed.

Brief amici curiae of 42 Professors of Law, Economics, Business, and Medicine filed.

Petition for a writ of certiorari filed. (Response due August 12, 2022)

Application (21A677) granted by The Chief Justice extending the time to file until July 11, 2022.

Application (21A677) to extend the time to file a petition for a writ of certiorari from May 12, 2022 to July 11, 2022, submitted to The Chief Justice.


Teva Pharmaceuticals USA, Inc., Petitioner, represented by William McGinley Jay

GlaxoSmithKline LLC, et al., Respondent, represented by Juanita R. Brooks

Amici Curiae

42 Professors of Law, Economics, Business, and Medicine, Amicus Curiae, represented by Charles Duan

Alvotech, Amicus Curiae, represented by Jonathan Yates Ellis

Association for Accessible Medicines, Amicus Curiae, represented by Matthew S. Hellman

Mylan Pharmaceuticals Inc., Amicus Curiae, represented by Steffen Nathanael Johnson

Last updated: January 30, 2023